Cargando…
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard therapeutic strategy for triple-negative breast cancer (TNBC). TNBC patients with residual disease after NAC have a significantly worse survival than those with pathological complete response (pCR); however, there is no apparent prognostic f...
Autores principales: | Tokunaga, Eriko, Fujita, Aya, Takizawa, Katsumi, Baba, Kimiko, Akiyoshi, Sayuri, Nakamura, Yoshiaki, Ijichi, Hideki, Masuda, Takanobu, Koga, Chinami, Tajiri, Wakako, Ohno, Shinji, Taguchi, Kenichi, Ishida, Mayumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314992/ https://www.ncbi.nlm.nih.gov/pubmed/29971631 http://dx.doi.org/10.1007/s12282-018-0888-y |
Ejemplares similares
-
Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
por: Tokunaga, Eriko, et al.
Publicado: (2021) -
The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution
por: Tokunaga, Eriko, et al.
Publicado: (2020) -
The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
por: Tajiri, Wakako, et al.
Publicado: (2020) -
Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan
por: Miyashita, Mika, et al.
Publicado: (2015) -
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000
por: Shigematsu, Hideo, et al.
Publicado: (2011)